Methods A systematic search was conducted using the Medline® and Embase® databases
up to 30 June 2017 employing specific medical subject heading terms. Additionally, the …

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the
inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis. Twenty …

Objectives According to guidelines, a nationwide non-medical switch from originator (INX,
Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients …

Biosimilars of infliximab were first approved by the European Medicine Agency in 2013, 1, 2
based on pre-clinical studies on biosimilarity and on clinical data coming from two …

Abstract Background and Aims: Biosimilar infliximab CT-P13 is approved for all indications
of the originator product in Europe. Prospective data on its efficacy, safety, and …

Background Few data are available on the safety and efficacy of infliximab biosimilar CT-
P13 in patients with ulcerative colitis and Crohn's disease. Methods A prospective …

Abstract Background and Aims: The biosimilar of Remicade®, CT-P13, recently entered the
European market. Clinical data on switching from Remicade® to CT-P13 in inflammatory …

Background Biosimilars of anti‐tumour necrosis factor (TNF)‐α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …

Background The efficacy, safety and immunogenicity risk of switching between an originator
biologic and a biosimilar or from one biosimilar to another are of potential concern …

Background and aims: The growing incidence of inflammatory bowel disease (IBD) in
children necessitates the use of biological treatments. Recently, an infliximab biosimilar was …